Immunology services for the development
of novel medicines

T lymphocytes mature into CD4- or CD8-expressing single positive cells in the thymus from where they become “peripheral T lymphocytes” which populate the secondary lymphoid organs. Upon interaction with antigen-presenting cells, peripheral T lymphocytes become activated, proliferate and expand to differentiate into effector and memory cells.

Until some years ago two functionally different CD4+ T helper (Th) cell types were known, i.e. “Th1 cells” which are induced by the action of IFN-gamma and IL-12 to protect against specific intracellular pathogens, and “Th2 cells” which are induced by IL-4 to encounter parasitic infections and also to participate in allergic reactions.
Additional CD4+ Th subtypes have been described meanwhile.

First the “Th17 effector T cell”, which produces IL-17 and IL-6 and which is generated by the action of IL-23. Th17 cells function to clear a range of pathogens distinct from Th1 and under pathological conditions they are involved in autoimmune responses. The latter has sparked general interest for these cells as targets for immuno-modulatory and anti-inflammatory therapies.

“Treg cells” (CD4+, CD25+, FoxP3+) represent another variant of CD4+ effector T-cells with a pivotal role in the regulation of immune responses.

FOCUS Immunology provides state-of-the-art scientific support and services to study these cell types under GLP conditions. If you are interested in learning more about FOCUS Immunology’s experience and offers or if you want to discuss your specific experimental needs, please feel free to contact:

Dr. Eddy Bruyns, Head of FOCUS Immunology Laboratory via e-mail eddy.bruyns@focus-cdd.com or via telephone +49 6221 64935124.

Bettelli et al Nat Immunol 2007 8:345-350
Shevach Immunol Rev 2006 212: 60-73
Murphy Nat Rev Immunol 2002 2: 933-944